The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Maciej Michal Mrugala on the Efficacy and Further Uses of Temozolomide in Gliomas

Maciej Michal Mrugala MD, PhD, MPH
Published Online:1:32 PM, Tue February 9, 2016

Maciej Michal Mrugala MD, PhD, MPH, chief of the Division of Neuro-Oncology, University of Washington’s School of Medicine, discusses the efficacy of temozolomide in gliomas. Mrugala says temozolomide is one of the few treatments that can effectively cross the blood-brain barrier, and is more bioavailable than most other treatments.

Mrugala adds that there are currently ongoing tests to study the efficacy of temozolomide given locally in animal models. He adds there are also studies looking into placing temozolomide into a polymer, which in turn would be placed into the resection cavity as another way of administering treatment.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.